Skip to main content
Medical Reference · Condition Monograph

Tracheal Cancer

기관암

A very rare cancer that begins in the "trachea," the passage through which air flows. Because its symptoms resemble those of asthma or bronchitis, diagnosis is often delayed, so careful evaluation of persistent respiratory symptoms is important.

History

Because malignant tumors of the trachea are very rare even among all cancers, for a long time simply distinguishing between "cancer that started in the trachea itself" and "cancer that spread in from surrounding organs" was a major challenge. In the past, because symptoms such as cough, wheezing, and shortness of breath resembled those of common respiratory diseases, the condition was often mistaken for asthma or chronic bronchitis, and because the disease was hard to see on a chest X-ray alone, diagnosis was frequently delayed. After bronchoscopy became widespread from the mid-20th century onward, it became possible to look directly inside the trachea and take tissue for examination, and thanks to this, the types of tumors originating in the trachea (squamous cell carcinoma, adenoid cystic carcinoma, etc.) were gradually classified.

In the 2000s, as chest computed tomography (CT) came into wide use, it became possible to evaluate relatively accurately the location and length of a tumor, the degree of airway narrowing, invasion of surrounding organs, and the presence of lymph node involvement. Tracheal surgery is a highly difficult operation that involves "cutting out part of the airway and joining it back together," so in the past the number of patients eligible for surgery was small and attempts were limited. Recently, as anesthesia and critical care technology, surgical techniques, the precision of radiation therapy, and airway management using bronchoscopy (laser, radiofrequency, stents, etc.) have advanced, the number of patients for whom surgery and treatment aimed at cure are possible has increased.

Because the number of patients with primary malignant tumors of the trachea is small, large-scale clinical trials are difficult, and there is no single established "right answer" for treatment. Recent review articles have been organized in the direction of emphasizing realistic decision-making flows such as "which patients should be considered for surgery first," "if surgery is difficult, how radiation therapy and chemotherapy should be combined," and "when and how endobronchial treatment should be used."

Causes

It is difficult to identify a single "cause" of tracheal cancer. However, among the representative malignant tumors arising in the trachea, squamous cell carcinoma is relatively well known to be associated with smoking. When the airway mucosa is exposed over a long period to the carcinogens in tobacco smoke, the mucosa can undergo degeneration (a process in which cells change abnormally), and when these changes accumulate, they can progress to cancer.

On the other hand, adenoid cystic carcinoma (cancer arising from the glandular system of the trachea) often has no clear association with smoking, and although it grows relatively slowly, it has a tendency to spread along nerves (perineural invasion), so local recurrence sometimes appears late. It is also very common for cancer of surrounding organs such as the thyroid, larynx, esophagus, or lungs, rather than cancer that started in the trachea itself, to grow and invade the tracheal wall, protruding into the inside of the trachea.

Realistically, clinical clues such as "smoking history," "the possibility of other accompanying airway cancers (laryngeal cancer, lung cancer, etc.)," and "whether symptoms persist for a long time without responding to asthma treatment" are important. In addition, chronic inflammation, past radiation exposure, and occupational inhalation exposure are sometimes cited as risk factors.

Genetic Epidemiology

Because primary malignant tumors of the trachea are not common cancers, studies that have analyzed genetic factors on a large scale are very limited. Taking the review articles to date together, no established single-gene variant is known that would justify saying "a specific gene is the cause" of primary tracheal cancer.

However, because squamous cell carcinoma has similarities to squamous cell carcinoma of the larynx and lungs, the possibility has been raised that it may share some patterns of smoking-related genetic damage. In addition, because adenoid cystic carcinoma is histologically similar in some respects to adenoid cystic carcinoma of the salivary glands, there is discussion that its tumor biology may be similar.

The clinically important point is that "tracheal cancer often appears to be associated with environmental exposure (particularly smoking), but the evidence is not sufficient to recommend screening or family testing based on genetic factors." Therefore, from the general public's point of view, it is more realistic for prevention to consist not of genetic testing but of avoiding smoking and being evaluated quickly when warning symptoms persist.

General Epidemiology

Primary malignant tumors of the trachea are a very rare disease, with annual incidence often reported as 1 or fewer per 100,000 population. They account for a very small proportion even among all respiratory cancers, occurring far less often than laryngeal cancer or lung cancer. Because the number of patients is small, national statistics are limited, and figures may differ slightly from study to study.

Sex and age vary according to the type of tumor. Squamous cell carcinoma is relatively associated with smoking and is reported more commonly among middle-aged and older adults, and many reports indicate that it is more frequent in men. Adenoid cystic carcinoma can also appear at relatively younger ages, and there are reports that it shows no clear sex difference. In terms of the distribution of histological types, squamous cell carcinoma and adenoid cystic carcinoma are known to account for a large proportion of primary malignant tracheal tumors in adults.

The prognosis is often determined largely by the "histological type" and "whether complete surgical resection is possible." In addition, delayed diagnosis because the symptoms are nonspecific is also pointed out as an important epidemiological problem.

Pathogenesis

The trachea is a tube through which air passes; its inside is covered with mucosa, and beneath that are cartilage, connective tissue, glands, and other structures. For squamous cell carcinoma, a process is described in which the surface cells of the tracheal mucosa are subjected to repeated irritation (typically smoking) and inflammation, so that the genes of the mucosal cells are damaged, normal regulation of cell division breaks down, and the cells progress to cancer. In this process, the mucosa can pass through "abnormal changes (precancerous changes)" and then develop into invasive cancer.

Adenoid cystic carcinoma is understood to begin in the glandular system beneath the mucosa. Although this tumor grows slowly, it can spread a long way along the tracheal wall, and because of its tendency to spread along nerves, microscopic residual lesions may remain even after the visible tumor is removed surgically. That is why it is important in treatment planning that the actual extent of invasion may be longer than the extent seen on imaging.

In common, as the tumor grows and narrows the tracheal lumen, shortness of breath, wheezing, and stridor appear, and if it irritates the mucosa or invades blood vessels, blood-streaked sputum (hemoptysis) can occur. In addition, if the tumor breaks through the tracheal wall and spreads into the surroundings, it can cause dysfunction of surrounding structures such as the thyroid, esophagus, and laryngeal nerves (hoarseness, difficulty swallowing, etc.).

Symptoms

The symptoms of tracheal cancer are easier to understand when divided into "symptoms of airway narrowing" and "symptoms that arise as the mucosa is damaged or the tumor spreads into the surroundings." The most commonly mentioned is a long-lasting cough. In tracheal cancer, a cough that lasts more than 2–3 weeks or gradually worsens and does not respond to existing treatment can be a clue.

Shortness of breath (dyspnea) is also important. At first, a person may feel short of breath only during exercise, but as the airway narrows further, they may feel short of breath even at rest. In addition, a whistling sound when breathing (wheezing) or harsh breathing sounds heard from the neck area (stridor) may appear, so it is sometimes mistaken for asthma. If symptoms continue despite asthma treatment, or if "asthma-like symptoms" suddenly begin at an older age, a structural problem of the airway, including the trachea, should be suspected.

Blood-streaked sputum (hemoptysis) is a warning symptom that can appear when the mucosa bleeds easily. Even if the amount is small, it must be evaluated if it recurs. Nonspecific symptoms such as chest pain or chest discomfort and a foreign-body sensation in the throat may also accompany it.

As the disease progresses, recurrent pneumonia or atelectasis (a condition in which part of the lung loses air and collapses) can develop. This is because the tumor obstructs the flow of air and the clearance of sputum, so that certain areas of the lung are repeatedly blocked.

Signs

Signs refer to objective findings confirmed on examination or testing. The most important sign in tracheal cancer is "signs of airway obstruction." Stridor, a particularly harsh, high-pitched sound when breathing in, can be a sign that the upper airway has narrowed, and in severe cases it can lead to an emergency. Signs of respiratory distress such as decreased oxygen saturation, increased respiratory rate, and use of accessory muscles may appear.

Wheezing may be heard on auscultation, and unlike in asthma, if it does not improve well with medication, is heard more clearly on one side, or is louder near the neck, structural narrowing is suspected. Recurrent pneumonia, atelectasis, and obstructive changes seen on imaging are also important signs.

If the lymph nodes in the neck or above the collarbone are enlarged, or a mass around the trachea can be felt, it may suggest an advanced lesion or metastasis. Hoarseness (voice changes) and difficulty swallowing can appear when the tumor has invaded the laryngeal nerve or the area around the esophagus.

In particular, hoarseness is also common in laryngeal diseases, but when it occurs together with shortness of breath or stridor, the possibility of an "airway tumor" should also be considered.

Screening

Currently, no "standard screening test" is recommended for detecting tracheal cancer early in the general population. The reason is that the occurrence of primary malignant tracheal tumors itself is so rare that if regular testing were performed on the entire population, the costs and unnecessary tests and side effects could outweigh the benefits gained.

However, "screening" in a realistic sense means not missing people who have risk factors or whose warning symptoms persist. For example, when a person has a heavy smoking history and newly developed wheezing or shortness of breath does not respond to asthma treatment, hemoptysis recurs, or there is recurrent pneumonia of unknown cause, it is important not to regard it simply as a cold or asthma but to carry out further evaluation.

The key to screening for tracheal cancer is not "fixed regular testing" but "recognizing symptoms as warning signs and, when necessary, promptly performing appropriate imaging and endoscopic examinations." Low-dose chest CT screening performed in groups at high risk of lung cancer targets lung cancer, but because the trachea is included in the imaging range, there is a possibility that a tracheal lesion may be discovered incidentally.

Diagnosis

The diagnosis of tracheal cancer usually proceeds in the order of (1) medical history and physical examination, (2) imaging, (3) confirmation and biopsy via bronchoscopy, and (4) staging and functional assessment. First, the physician listens in detail about the duration of symptoms, the pattern of worsening, smoking history, whether there have been recurrent infections, and whether there has been hemoptysis, and checks for signs of respiratory distress and stridor.

The key imaging test is chest computed tomography (CT). Contrast-enhanced CT is useful for evaluating the location of the tumor (upper/middle/lower trachea), its length, how much the tracheal lumen has narrowed, whether it has spread outside the tracheal wall, its relationship with surrounding organs, and the lymph nodes. If necessary, MRI can be used to look at soft tissue invasion in more detail, and PET-CT can help with evaluating distant metastasis and systemic staging.

The diagnosis is confirmed with endoscopy and biopsy. By viewing the lesion directly with a bronchoscope and taking tissue for pathological examination, the type of cancer can be confirmed. When the airway is severely narrowed, the test itself can be dangerous, so it is important for an experienced team to also plan how to secure the airway (emergency intubation, stents, laser resection, etc.).

It is very important to distinguish whether the cancer is primary or whether cancer from another organ has invaded the trachea. This distinction is made by combining imaging, pathology, and evaluation of surrounding organs, because the treatment strategy differs.

Treatment

Treatment can be broadly divided into "treatment aimed at cure" and "treatment centered on symptom relief (securing the airway)." Which treatments are possible for a patient depends on the type of tumor, its size and length, whether there is invasion of surrounding areas, whether there is metastasis, and the patient's overall condition. When possible, surgical resection is cited as the most important treatment. Surgery that removes part of the trachea and reconnects the remaining trachea is technically difficult, but if complete resection is possible, the likelihood of long-term survival increases.

After surgery, radiation therapy is sometimes added depending on the possibility of cancer remaining at the resection margins, the type of tumor, and the extent of invasion. In particular, because microscopic residual disease can be a problem in adenoid cystic carcinoma, a strategy of combining it with radiation therapy is discussed. When surgery is difficult or there is metastasis, radiation therapy, chemotherapy, or a combination of the two is considered.

Bronchoscopic treatment plays a very practical role. With laser, radiofrequency, cryotherapy, mechanical resection, airway stent placement, and so on, the narrowed airway can be widened to make breathing easier. This can be used when the airway must be secured as an emergency, to stabilize the condition before radiation therapy or chemotherapy, or to improve quality of life in situations where curative treatment is difficult. Because there are also risks such as bleeding, perforation, and stent complications, it is important for it to be performed at an experienced institution.

Prognosis

The prognosis depends greatly on several factors. The first is the type of tumor (histological type). Adenoid cystic carcinoma generally progresses relatively slowly and long-term survival is possible in some cases, but it is known that recurrence can appear late, so long-term follow-up is needed. Squamous cell carcinoma, on the other hand, is often associated with smoking and can progress rapidly, and if invasion of surrounding areas or metastasis is already present at diagnosis, the prognosis can become unfavorable.

The second is whether complete surgical resection is possible. A good prognostic factor repeatedly emphasized in review articles is "complete resection (negative resection margins)." Conversely, if cancer remains at the resection margins, there is deep invasion of surrounding organs, or there is lymph node metastasis, the prognosis can worsen.

The third is the timing of diagnosis. Because the symptoms of tracheal cancer are similar to those of asthma or bronchitis, diagnosis tends to be delayed, and in some cases it is discovered only after the airway has narrowed considerably. Therefore, getting a detailed diagnosis quickly in the situation where "symptoms persist for a long time without responding to treatment" can indirectly affect the prognosis.

After treatment, surveillance for recurrence is important. In particular, because local recurrence or distant metastasis may be discovered years later with some tumors, monitoring for changes in symptoms and regular imaging/endoscopic follow-up are recommended in some cases. The individual follow-up plan varies according to the treatment method and the level of risk.

Prevention

No method is known to prevent primary malignant tumors of the trachea 100%, but there are realistic strategies that reduce the risk and increase the likelihood of early detection. The most important is quitting smoking. In particular, because squamous cell carcinoma is frequently mentioned in connection with smoking, not starting to smoke, or quitting as soon as possible if one already smokes, helps lower the risk of cancer throughout the airway (larynx, trachea, lungs). Reducing secondhand smoke is also important.

The second is not dismissing "warning symptoms" lightly. If there is a cough that lasts more than 2–3 weeks or worsens, newly developed wheezing or stridor, shortness of breath, recurrent hemoptysis, or recurrent pneumonia or atelectasis, one should not think of it simply as a cold or asthma but should consider appropriate tests such as chest CT. The third is reducing occupational and environmental inhalation exposure. In work environments with continuous exposure to certain dusts or chemicals, wearing protective equipment and ventilating the workplace are important.

People who have already been treated for another airway cancer (laryngeal cancer, lung cancer, etc.) are advised to maintain a good follow-up plan with their medical team. Because the airway mucosa may be damaged throughout, faster evaluation may be needed if new symptoms develop.

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.